摘要
硼替佐米用于治疗复发性和难治性多发性骨髓瘤已取得显著效果,研究表明,该药同样能对白血病发挥良好的抗肿瘤作用。无论是实验研究还是临床研究,硼替佐米治疗慢性粒细胞白血病、慢性淋巴细胞白血病、急性髓性白血病、急性淋巴细胞白血病、成人T淋巴细胞白血病和浆细胞白血病均取得了一定的进展。本文就硼替佐米对各种白血病细胞的分子生物学作用机制、该药治疗白血病的临床实验结果以及它联合其它抗肿瘤药物治疗白血病效果进行简要阐述。
Bortezomib is an effective drug for patients with relapsed or refractory multiple myeloma. By experiment and clinical research, it has made many progresses of Bortezomib in the treatment of chronic myeloid leukemia, chronic lymphocytic leukemia, acute myeloid leukemia, acute lymphocytic leukemia, adult T-cell leukemia and plasma cell leukemia. Both the mechanisms of Bortezomib on all of the leukemia cell lines and the clinical effects of this drug alone or with other chemotherapeutic agents on leukemia were reviewed in this article.
出处
《国际内科学杂志》
CAS
2008年第5期291-294,共4页
International Journal of Internal Medicine